Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection Clinical Trials

1 actively recruiting trial across 1 location

Also known as: PHESGO, Pertuzumab-Trastuzumab FDC SC

Filter by location:

Boston, Massachusetts1 trial

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.